A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Participants with Moderate to Severe Plaque Psoriasis
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
75
Active Treatment
Identical Tablet
Study Center
Birmingham, Alabama, United States
RECRUITINGImprovement in PASI-90
Proportion of participants achieving at least a 90% improvement from baseline in Psoriasis Area and Severity Index (PASI-90) at Week 12
Time frame: Assessment completed after 12 weeks of treatment/placebo
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Study Center
Phoenix, Arizona, United States
NOT_YET_RECRUITINGStudy Center
Chula Vista, California, United States
RECRUITINGStudy Center
Fountain Valley, California, United States
NOT_YET_RECRUITINGStudy Center
Fremont, California, United States
NOT_YET_RECRUITINGStudy Center
Los Angeles, California, United States
NOT_YET_RECRUITINGStudy Center
Los Angeles, California, United States
NOT_YET_RECRUITINGStudy Center
San Diego, California, United States
NOT_YET_RECRUITINGStudy Center
Fort Lauderdale, Florida, United States
NOT_YET_RECRUITINGStudy Center
Miramar, Florida, United States
NOT_YET_RECRUITING...and 10 more locations